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Taiwan has the highest incidence and prevalence of end-
stage renal disease (ESRD) according to international
comparisons of the United States Renal Data System
report.1 Chronic kidney disease (CKD) is a global
public health challenge because of its increasing number
of patients, strong association with adverse cardiovas-
cular outcomes, and high risk of progression to ESRD.2
Many studies have been performed to establish the role
of estimated glomerular filtration rate (eGFR) screening
for CKD, with or without concomitant proteinuria
screening. However, the risk of renal failure in patients
with “under-recognized CKD” has not been assessed.
In this issue of the Journal of the Chinese Medical
Association, Wu et al3 are the first to report such esti-
mates. They reported that stage 3B CKD (eGFR,
30–44mL/min/1.73m2) with a normal routine clinical
assessment (i.e. under-recognized CKD) and stage 5
CKD (eGFR, < 15 mL/min/1.73 m2) have a similar
risk of renal failure, which is significantly higher than
the other CKD groups.
The high risk of renal failure among patients with
under-recognized stage 3B CKD is surprising and may
even be misleading. Prognosis associated with a given
level of eGFR varies substantially based on the presence
and severity of proteinuria.4 Patients with heavy pro-
teinuria but without overtly abnormal eGFR appear
to have worse clinical outcomes than those with mod-
erately reduced eGFR but without proteinuria as shown
in a prospective cohort study based on 462,293 adults
in Taiwan.5 When stage 3 CKD is unaccompanied by
other manifestations of kidney disease, such as protein-
uria, it may be of little clinical consequence and is
mainly a manifestation of age, sex, and race effects. In
a long-term (25-year follow-up) longitudinal study of
men with a high risk of cardiovascular disease (the
Multiple Risk Factor Intervention Trial study),6 it was
found that an eGFR of < 60 mL/min/1.73 m2 in the
absence of “dipstick-positive” proteinuria had a positive
predictive value of only 5.6% for the future develop-
ment of ESRD. However, the addition of more than
1+ proteinuria to an eGFR of < 60 mL/min/1.73 m2
substantially improved the positive predictive value to
approximately 26%. The majority of patients who are
destined to develop ESRD would not be detected by a
screening program based on eGFR alone. The intro-
duction of the Kidney/Dialysis Outcomes Quality
Initiative (K/DOQI) classification of CKD represented
a major step forward for clinicians and researchers,7
but population-based studies suggest that the combined
consideration of both parameters of kidney function,
proteinuria and eGFR, may be the most effective in
assessing prognosis.
Although a large cohort of 15,817 patients was
screened in the present study, analytic power might
still be limited and several issues need to be clarified.
First, the cohort was not representative of the general
population but was limited to individuals who partici-
pated in a self-pay standard medical screening program
in health management centers. Some participants may
already have had underlying health problems or be
members of large families. CKD is known to prevail in
patients with medical illness and within families. Wu
et al3 reported a prevalence rate of 10.1% of CKD stages
3–5 in this cohort, which was much higher than the
6.9% in subjects older than 20 years of age in a nation-
wide, randomized, stratified survey for hypertension,
hyperglycemia and hyperlipidemia (the TW3H survey)
by Hsu et al.8 In addition, use of an absolute threshold
of eGFR for defining stage 3 CKD (30–59 mL/min/
1.73 m2) without any adjustment for the effects of
normal aging on eGFR by the K/DOQI may overes-
timate the prevalence of CKD.7
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Second, the authors failed to use more than 1 mea-
sure of urine protein in their study patients. Proteinuria
may have been misclassified because of the common
variability based on a single urine measurement,9 and
this may be why proteinuria was not consistent with
clinically relevant outcomes in the current study.
Third, the authors did not have information on
characteristics such as comorbidities, smoking and the
use of medications, which may have resulted in resid-
ual confounding. Given the small numbers of patients
with under-recognized stage 3B CKD and the low
occurrence of dialysis observed in their study, it is
likely that further adjustment for these covariables
would negate the observed associations.
Finally, the follow-up in this study was relatively
short to assess progression to renal failure, especially for
people with high levels of baseline eGFR. The short
follow-up of the study may have limited the ability to
discern a significant difference in the progression to
ESRD or a need for dialysis that might have developed
at later time points as seen in studies with long-term
follow-up. Furthermore, Wu et al3 assessed the inci-
dence of renal failure requiring dialysis within 2 years
after standard medical screening, which may have
included some participants with acute renal failure as
well as those with progression of CKD. However, the
authors did not separately report the rate of acute or
chronic dialysis.
In the current study,3 the hazard ratios for renal
failure for patients categorized as having stage 3A CKD
(eGFR, 45–59 mL/min/1.73 m2) without protein-
uria were significantly lower than those for patients with
stage 3B CKD (eGFR, 30–44 mL/min/1.73 m2).
These data suggest that the effect of a low eGFR in the
absence of proteinuria is not seen until the eGFR falls
below the normal levels expected after adjusting for age
and sex effects (approximately 45 mL/min/1.73 m2).
A reduced eGFR, particularly in the range of
30–44 mL/min/1.73 m2, is likely to be a risk factor
of cardiovascular events and progression to ESRD.
However, the effect of a reduced eGFR alone, the 
so called “under-recognized CKD”, on prognosis is
questionable. In our opinion, universal eGFR-based
screening would be of little value in predicting ESRD
without a concomitant consideration of the presence or
absence of proteinuria. It is likely that a more targeted
and multiphasic approach might enhance the per-
formance of such screening and would be more cost-
effective. It is currently unknown whether or not
early identification and treatment of subjects with
stage 3B CKD on the basis of eGFR, but without any
other manifestations of kidney disease, would reduce
the subsequent risk of progression to ESRD.10
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